Member Info for BertieBassett

There are other shares out there that are offering "instant" cash - i.e. AST ... and even HVIVO ... so PI's are playing with their investments - as they should ...

We are quite solid here with the research ... and the buying over the past few days indicates news to come ...

Hold! Hold! Hold!

-- BB --

Hi,
I think Shell is trying to get away from P&G ... (according to last Annual Report)
But there is possibly another of the Big 9 in the wings!
--BB--

Usually in this type of drill, the chances of success are 10 - 12% (industry norm).

According to the CPR: BPC has a "score" of 25 - 35%.

enough said!

-- BB --

For some reason, I cannot sleep ... 0530 and it's still dark in North Devon! Time for FARN research!

-- May 8th 2018 - SP down as much as 90% - from 725 to to end at 104 after clinical results re: Traumakine
Boss - Dr Jalkanen - "disappointed" BUT looks forward to more results on drug 3rd Qtr from Japan.
(In 2016, Maruishi produces positive Phase II results for Traumakine).

Euros 18.7 million in bank

Focus on Clevegen. FARN working with Birmingham Uni Medical School's world-renowned liver unit.
"CTA filing for drug in UK - 3rd Qtr 2018"

-- June 19th 2018 - "important observations" from Traumakine failure (Dr J.)

-- June 19th - 21st 2018 - Directors and associates of FARN buy 124,100 shares in FARN - between 56 & 71pps

-- June 28th 2018 - Clevegen shows "encouraging results" (Dr J).
SP up 36% - "CTA filings 3rd Qtr with patients recruited for 4th Qtr" - Phase I/II

-- August 8th 2018 - Abzena announces it has completed manufacture of cancer drug Clevegen in California.
(Abzena was called Antitope (based in Cambridge) and has been working with Faron since 2010)

SO - what are we waiting for in this 3rd Qtr:

-- Traumakine top line results from Japan
-- Potential new model for Traumakine
-- Clevegen filings in UK and more pre-clinical results

Seems to me that despite Traumakine, FARN has a real chance to turn things around with Clevegen ...

Oversold but market saw Traumakine as a huge failure ... for now. Maybe Japan has something in store for us? Good news from Traumakine or Clevegen - then SP will push back to April/early May mark.

Here's hoping ...

BTW - the BOD for Faron are quite accomplished in biotech and medicine ... I cannot see them taking "failure" lightly ...

Back to bed I think!

-- BB --

it's good to see ....

-- BB --

i was about to say ... the SP has dropped a little and everyone here is quite chilled about it!

REFRESHING!!!

-- BB --

Hi,

I tried to buy MKA on the AJ Bell platform ... I couldn't.

I was told it was due to MKA being domiciled in Canada?!

Has anyone else had a similar experience?

thanks, -- BB --

thank you ... i am knee-deep in FARN today ... so I am happy but I would like to be ecstatic!

-- BB --

I am looking at SRSP today ... interesting ...
-- BB --

Hi Tomie ... I like your enthusiasm ... in fact applaud it ... I would dearly love to see GDP10 a share ... and it IS achievable ... BUT we will need firm positive news from FARN ... it's forays in Japan ... and and and ...

Clevegen is the key ...

There are a couple of other pharmas out there that are in similar positions ... just one breakthrough and PIs will be pleased ...

-- BB --

After a "large" day like yesterday, I always hold my breath the next morning for the RNS saying .. "Board knows no reason etc etc" .... BUT none of that today ... Maybe, the "Board DOES know a reason"!! Here's hoping ...

-- BB --

what's not to love about Faroe? Solid set of results ... t/o still on cards for this year ...
-- BB --

In case you missed it:

Abzena plc
Release of first GMP drug substance for an ABZENA Inside product manufactured by Abzena
Cambridge, UK, 8 August 2018 - Abzena plc (AIM: ABZA, 'Abzena'), the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has completed the GMP drug substance manufacture of an ABZENA Inside product that was originally humanised utilising Abzena's Composite Human Antibody platform™. The product is a novel therapeutic antibody, Clevegen®, being developed by clinical stage biotechnology company, Faron Pharmaceuticals.

if truth be told, i am not an ice cream fan ... !

yes - at the moment, life-changing shares - FARN, BPC ... and HVO ... it will happen in a blink of an eye ...

-- BB --

SO many times in the past few weeks I have thought "Sell Farn" ... and I didn't ... so today is a lovely surprise ...
SO many times in the past few weeks I have though "Sell Hvo" ... and I haven't ...
The research on HVO is sound ... and the investors who have pumped in millions aren't doing it for a loss or fun ... but to line their pockets on the success of a "cure" for flu! While I haven't invested millions, I have invested enough to ensure when it all comes good, I can eat Rockie Road for the rest of my life (washed down with a D'Yquem 1970)!
Hold Hold Hold (and maybe add?) ... our time will come ...

-- BB --
Fortune favours the Brave

If a top 10 international oilie is poised to inject cash into a small cash-poor company, it will want to see diligence on behalf of management pay... What it wouldn't want to see is cash being invested and suddenly the CEO gets huge emoluments... A smart move... -- BB --

please remember that the Bahamian Government has a cut too ...

So ... Shell ... Moving it's regional HQ to the Bahamas ... Building a new power plant ... AND the government is "hell-bent" on the Oban deal ... All information from local Bahamian newspapers... SHELL... 🙂

on less than a dozen trades!

Um ... With no disrespect Kapkina ... I do not understand your post in any way ... But thank you for replying... -- BB --